Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...
New Report Shows Link Between Ending HIV And Upholding Human Rights
Here are some of the findings from UNAIDS' new report on HIV and human rights, and what they could mean for the fight against ...
Managed Healthcare Executive1d
Lupin's Generic HIV Treatment for Children Receives Tentative FDA Approval
This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who ...
Reuters11d
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent ...
Rolling Out12d
How new HIV prevention strategies are changing lives
Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...
Atlanta Journal-Constitution5d
Atlanta struggles to reduce HIV rates
It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...
HIV pioneers are aging faster than normal, prompting new approaches to care
But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...
WHYY11d
Drugmakers hiked prices for hundreds of drugs in early January
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...
Fiji HIV outbreak: Too early to tell of impact on NZ, charity says
It is too early to tell what impact the current HIV outbreak in Fiji may have on New Zealand, a charity at the forefront of ...